| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Climb Bio, Inc. | SVP, Finance & CAO | Restricted Stock Units | 15,000 | $40,400 | $2.02 | 18 Jun 2025 | Direct |
| Climb Bio, Inc. | SVP, Finance & CAO | Common Stock | 18,888 | $23,421 | $1.24 | 20 Jun 2025 | Direct |
| Climb Bio, Inc. | SVP, Finance & CAO | Stock Option (Right to Buy) | 100,000 | 13 Jan 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| CLYM | Climb Bio, Inc. | 18 Jun 2025 | 3 | -$1,540 | 4 | SVP, Finance & CAO | 20 Jun 2025, 16:20 |
| CLYM | Climb Bio, Inc. | 18 Mar 2025 | 3 | -$1,571 | 4 | SVP, Finance & CAO | 20 Mar 2025, 17:21 |
| CLYM | Climb Bio, Inc. | 13 Jan 2025 | 1 | $0 | 4 | SVP, Finance and CAO | 15 Jan 2025, 16:15 |
| CLYM | Climb Bio, Inc. | 18 Dec 2024 | 3 | -$2,495 | 4 | CHIEF ACCOUNTING OFFICER | 20 Dec 2024, 16:15 |
| CLYM | Eliem Therapeutics, Inc. | 18 Sep 2024 | 4 | -$9,741 | 4 | CHIEF ACCOUNTING OFFICER | 20 Sep 2024, 21:53 |
| CLYM | Eliem Therapeutics, Inc. | 18 Jun 2024 | 3 | -$8,982 | 4 | CHIEF ACCOUNTING OFFICER | 21 Jun 2024, 14:57 |
| CLYM | Eliem Therapeutics, Inc. | 18 Mar 2024 | 1 | $0 | 4 | CHIEF ACCOUNTING OFFICER | 20 Mar 2024, 16:33 |
| CLYM | Eliem Therapeutics, Inc. | 13 Mar 2023 | 0 | $0 | 3 | Chief Accounting Officer | 21 Mar 2023, 10:21 |